医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jinchi Biotech’s Giant Salamander Glycopeptides Research Paper Published in ‘Chinese Medical Cosmetology’

2014年10月13日 PM04:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

Jinchi Biotech Ltd. announced that ‘The Giant Salamander Glycopeptides in Resisting Skin Photo-aging Clinical Research’ has been published in ‘Chinese Medical Cosmetology’ Periodical (Volume 4, Issue 3, 2014).

Since 2012, Jinchi Biotech Ltd. has completed 40 cases of clinical observations and research on ‘Giant Salamander Glycopeptides (ADGPs) in resisting skin photo-aging’ with Aesthetic & Laser Plastic Surgery Center of PLA Air Force General Hospital (Professor: Xiaozhong Zhao, Ning Wei, Liangzhen Zhang) and Changsha Yahan Medical Beauty Hospital (Professor: Min Zhou, Jun Guo, Yangli Luo). The research results had proved that ADGPs can be applied to cosmetic and skincare products.

ABOUT JINCHI

www.jc-biotech.com

Owning the world’s only Giant Salamander Museum, Jinchi Biotech Ltd. mainly specialized in the R&D of giant salamander related biotech products with more than 40 skincare and health products under two product lines, namely SHINIQUE and ANDRIAS. With strong scientific research background and a comprehensive business model, Jinchi Biotech Ltd. values virtue and goodwill, commits to deliver quality products to consumers, and devotes to the health, beauty and biomedical industries.

Disclaimer

The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.

CONTACT

Jinchi Biotech Ltd.
Chan Luo, +86-731-8979-2661
ir@jc-biotech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表